Related content

Istradefylline, a novel adenosine A_2A receptor antagonist, for the treatment of Parkinson’s disease

By Jenner Peter  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 729-738

Informa Healthcare

Access to resources Recommend Favorite

Adenosine A 2A receptor antagonists as new agents for the treatment of Parkinson's disease

By Richardson P.J.   Kase H.   Jenner P.G.  

Trends in Pharmacological Sciences, Vol. 18, Iss. 9, 1997-10 ,pp. : 338-344

Elsevier

Access to resources Recommend Favorite

Istradefylline for the treatment of Parkinson's disease

By Park Ariane   Stacy Mark  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 111-114

Informa Healthcare

Access to resources Recommend Favorite

Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

By Müller Thomas  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1015-1024

Informa Healthcare

Access to resources Recommend Favorite

Novel therapy in Parkinson's disease: adenosine A_2A receptor antagonists

By Szabóó Nikoletta   Kincses Zsigmond Tamáás   Véécsei Láászlóó  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 4, 2011-04 ,pp. : 441-455

Informa Healthcare

Access to resources Recommend Favorite